Literature DB >> 12972634

The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.

Michael Overholtzer1, Pulivarthi H Rao, Reyna Favis, Xin-Yan Lu, Michael B Elowitz, Francis Barany, Marc Ladanyi, Richard Gorlick, Arnold J Levine.   

Abstract

The p53 gene is a critical tumor suppressor that is inactivated in a majority of cancers. The central role of p53 in response to stresses such as DNA damage, hypoxia, and oncogene activation underlies this high frequency of negative selection during tumorigenic transformation. Mutations in p53 disrupt checkpoint responses to DNA damage and result in the potential for destabilization of the genome. Consistent with this, p53 mutant cells have been shown to accumulate genomic alterations in cell culture, mouse models, and some human tumors. The relationship between p53 mutation and genomic instability in human osteosarcoma is addressed in this report. Similar to some other primary human tumors, the mutation of p53 correlates significantly with the presence of high levels of genomic instability in osteosarcomas. Surprisingly, osteosarcomas harboring an amplification of the HDM2 oncogene, which inhibits the tumor-suppressive properties of p53, do not display high levels of genomic instability. These results demonstrate that the inactivation of p53 in osteosarcomas directly by mutation versus indirectly by HDM2 amplification may have different cellular consequences with respect to the stability of the genome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972634      PMCID: PMC208795          DOI: 10.1073/pnas.1934852100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control.

Authors:  H Willers; E E McCarthy; B Wu; H Wunsch; W Tang; D G Taghian; F Xia; S N Powell
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

2.  Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.

Authors:  S Fang; J P Jensen; R L Ludwig; K H Vousden; A M Weissman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

Review 3.  Comparative genomic hybridisation.

Authors:  M M Weiss; M A Hermsen; G A Meijer; N C van Grieken; J P Baak; E J Kuipers; P J van Diest
Journal:  Mol Pathol       Date:  1999-10

Review 4.  Mutation detection in K-ras, BRCA1, BRCA2, and p53 using PCR/LDR and a universal DNA microarray.

Authors:  R Favis; F Barany
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

5.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

6.  Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability.

Authors:  I B Georgiades; L J Curtis; R M Morris; C C Bird; A H Wyllie
Journal:  Oncogene       Date:  1999-12-23       Impact factor: 9.867

7.  Homologous and nonhomologous recombination resulting in deletion: effects of p53 status, microhomology, and repetitive DNA length and orientation.

Authors:  D Gebow; N Miselis; H L Liber
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

8.  Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

Authors:  J Roth; M Dobbelstein; D A Freedman; T Shenk; A J Levine
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

9.  Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.

Authors:  H H Schlechte; M D Sachs; S V Lenk; S Brenner; B D Rudolph; S A Loening
Journal:  Cancer Detect Prev       Date:  2000

10.  Chromosomal regions involved in the pathogenesis of osteosarcomas.

Authors:  C Stock; L Kager; F M Fink; H Gadner; P F Ambros
Journal:  Genes Chromosomes Cancer       Date:  2000-07       Impact factor: 5.006

View more
  71 in total

Review 1.  Links between mutant p53 and genomic instability.

Authors:  Walter Hanel; Ute M Moll
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

2.  NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin signaling.

Authors:  Ajimu Keremu; Xiayimaierdan Maimaiti; Abudusaimi Aimaiti; Maimaiaili Yushan; Yamuhanmode Alike; Yilizati Yilihamu; Aihemaitijiang Yusufu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.

Authors:  Sara Del Mare; Kyle C Kurek; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  Am J Cancer Res       Date:  2011-04-03       Impact factor: 6.166

5.  Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors:  Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-05-30       Impact factor: 3.167

6.  Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.

Authors:  Xin-Yan Lu; Yaojuan Lu; Yi-Jue Zhao; Kim Jaeweon; Jason Kang; Li Xiao-Nan; Gouqing Ge; Rene Meyer; Laszlo Perlaky; John Hicks; Murali Chintagumpala; Wei-Wen Cai; Marc Ladanyi; Richard Gorlick; Ching C Lau; Debananda Pati; Michael Sheldon; Pulivarthi H Rao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

Review 7.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

8.  The expression and significance of IDH1 and p53 in osteosarcoma.

Authors:  Xiang Hu; Ai-Xi Yu; Bai-Wen Qi; Tao Fu; Gang Wu; Min Zhou; Jun Luo; Jun-Hua Xu
Journal:  J Exp Clin Cancer Res       Date:  2010-05-07

9.  Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription.

Authors:  Fenyong Chen; Jiadong Mo; Li Zhang
Journal:  Tumour Biol       Date:  2016-07-27

10.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression.

Authors:  Ou Ma; Wei-Wen Cai; Lars Zender; Tajhal Dayaram; Jianhe Shen; Alan J Herron; Scott W Lowe; Tsz-Kwong Man; Ching C Lau; Lawrence A Donehower
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.